


Ask a doctor about a prescription for ACICLOVIR SALA 250 mg POWDER FOR SOLUTION FOR INFUSION
Patient Information Leaflet
Aciclovir Sala 250 mg powder for solution for infusion EFG
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
In this leaflet:
Aciclovir Sala is a medicine that contains the active substance called aciclovir. Aciclovir belongs to a group of medicines called antivirals, which are active against herpes viruses. It works by eliminating or stopping the growth of viruses.
This medicine is indicated for:
Do not use Aciclovir Sala:
Warnings and precautions
Be especially careful with Aciclovir Sala:
Consult your doctor or nurse before starting to use aciclovir:
If you are not sure about the above circumstances, consult your doctor or nurse before using aciclovir.
Other medicines and Aciclovir Sala
Tell your doctor, pharmacist, or nurse if you are taking, or have recently taken, any other medicines, including those obtained without a prescription.
It is especially important that you talk to your doctor or pharmacist if you are taking any of the following medicines:
Pregnancy and Breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medicine.
The safety of this medicine in pregnant women has not been established, and it will only be used in cases where the benefit-risk assessment by your doctor advises its use.
Aciclovir is excreted in breast milk, and breastfeeding is not recommended during treatment.
Driving and using machines
No data are available to limit this activity.
Important information about some of the ingredients of Aciclovir:
This medicine contains 26 mg of sodium per vial (main component of table/cooking salt). This is equivalent to 1.3% of the maximum recommended daily intake of sodium for an adult.
You should never administer the medicine yourself. The medicine will always be administered by a trained person. Aciclovir will be given to you as a continuous infusion into a vein. This is where the medicine is administered slowly over 1 hour.
Aciclovir is usually administered every 8 hours.
You may receive fluids to ensure you do not become dehydrated.
The dose, frequency, and duration of the dose will depend on:
Your doctor may adjust the dose of aciclovir if:
Talk to your doctor before undergoing aciclovir if any of the above conditions apply to you.
Use in children
The dose of aciclovir given to:
If a child has kidney problems, the dose of the medicine may be reduced.
Use in elderly
The dose should be reduced in patients with renal impairment.
Your doctor will indicate the dose and duration of your treatment with intravenous aciclovir. In acute herpes simplex virus infections, 5 days of treatment is usually sufficient, but the duration of treatment will depend on the severity of the infection, the patient's condition, and response to treatment. The treatment of herpetic encephalitis and neonatal herpes simplex usually lasts 10 days. The duration of prophylactic administration of intravenous aciclovir will be determined by the duration of the risk period.
If you use more Aciclovir Sala than you should:If you think you have received too much aciclovir, talk to your doctor or nurse immediately.
If you have received too much aciclovir, you may: feel confused or agitated, have hallucinations (see or hear things that do not exist), have convulsions, lose consciousness (coma).
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to use Aciclovir Sala
Do not administer a double dose to make up for forgotten doses.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
This medicine can cause the following side effects:
Allergic reactions(affect less than 1 in 10,000 people)
If you have an allergic reaction, stop taking aciclovir and talk to your doctor immediately. The signs may include:
Other side effects include:
Common(affect less than 1 in 10 people)
Uncommon(affect less than 1 in 100 people)
Rare(affect less than 1 in 1,000 people)
Reporting of side effects
If you experience any side effects, talk to your doctor or nurse, even if it is possible side effects not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep Aciclovir Sala out of the sight and reach of children.
This medicine does not require special storage conditions.
Do not use this medicine after the expiry date stated on the label and carton after EXP. The expiry date is the last day of the month indicated.
The solutions obtained after reconstituting the vial with 10 ml of water for injection maintain their stability for 12 hours at 25°C or for 24 hours at 2°C-8°C.
From a microbiological point of view, the solution should be used immediately after preparation. If not used immediately, the time and conditions of storage before use are the responsibility of the user.
Do not use this medicine if you observe any visible turbidity or crystallization in the solution.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Aciclovir Sala
Appearance of the product and pack contents
Aciclovir Sala is presented in glass vials containing a white or almost white sponge-like tablet, closed with a rubber stopper and sealed with a closure cap.
The 250 mg dose is available in 10 ml vials, in packs of 5 and 50 vials.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer:
Laboratorio Reig Jofré, S.A.
Gran Capitán, 10 - 08970 Sant Joan Despí - Barcelona - Spain
Date of last revision of this leaflet: February 2023
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
This information is intended only for healthcare professionals
The solution should be administered only by intravenous route and in a continuous but very slow manner, so that it is administered over a period of not less than one hour.
Reconstitution and/or dilution is recommended immediately before use. The vial does not contain any preservative, so the unused solution should be discarded. If visible turbidity or crystallization appears before or during infusion, the solution should be rejected. The diluted solution should not be stored in the refrigerator.
Reconstitution of the lyophilized product:
The vial of intravenous aciclovir, which contains 250 mg of lyophilized aciclovir, should be reconstituted by adding 10 ml of water for injection or sodium chloride (0.9%) solution for intravenous infusion. The concentration of the reconstituted solution is 25 mg/ml.
Method of administration
Intravenous direct:
The reconstituted solution is administered using a controlled-rate infusion pump over a period of not less than one hour.
Intravenous infusion:
The reconstituted solution can be diluted for administration by infusion. The dilution is made totally or partially, depending on the required dose, by adding and mixing it with at least 100 ml of infusion solution, to obtain a solution with a maximum concentration of 0.5% (250 mg/50 ml). The contents of 2 vials (500 mg of aciclovir) can be added to 100 ml of infusion solution, and if the required dose is higher than 500 mg, a second volume of infusion solution can be used.
Aciclovir intravenous is compatible with the following infusion solutions:
Aciclovir intravenous, once added to the infusion solution, should be shaken vigorously to ensure perfect mixing.
After accidental infusion of intravenous aciclovir, severe inflammation of the extravascular tissue may occur, sometimes followed by ulcers. Infusion using mechanical pumps poses greater risks than gravity infusion. Phlebitis and inflammation at the infusion site may occur.
Expiry date
Do not use Aciclovir Sala 250 mg powder for solution for infusion after the expiry date stated on the packaging.
Date of last revision of this leaflet: February 2023
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for ACICLOVIR SALA 250 mg POWDER FOR SOLUTION FOR INFUSION – subject to medical assessment and local rules.